HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alex Minter Selected Research

IPH-2101

6/2014A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alex Minter Research Topics

Disease

2Neoplasms (Cancer)
01/2021 - 02/2011
1Smoldering Multiple Myeloma
06/2014
1Monoclonal Gammopathy of Undetermined Significance
06/2011
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/2011
1Hematologic Neoplasms (Hematological Malignancy)
02/2011
1Carcinogenesis
02/2011
1Multiple Myeloma
02/2011

Drug/Important Bio-Agent (IBA)

1IPH-2101IBA
06/2014
1Immunoglobulins (Immunoglobulin)IBA
06/2011
1Imatinib Mesylate (Gleevec)FDA Link
02/2011
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2011
1Proteins (Proteins, Gene)FDA Link
02/2011
1Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA
02/2011
1Proteasome InhibitorsIBA
02/2011
1Bortezomib (Velcade)FDA Link
02/2011

Therapy/Procedure

1Aftercare (After-Treatment)
01/2021
1Therapeutics
02/2011